Precidiag is at the forefront of a revolution in the discovery and development of precision therapeutics for chronic and systemic diseases.
In the past, little was known about the importance of the gut microbiome - the over thirty-five trillion microorganisms that live within the human gut. We now know that these microorganisms play a central role in human health and development.
Precidiag’s proprietary discovery platform utilizes advanced metagenomics, metabolic pathway analysis, and machine learning to identify biological pathways and biomarkers that decode this component of human health.
Artificial intelligence (AI) is employed to identify and prioritize precision therapeutics with improved response rates and fewer side effects.